COVID-19 Vaccine Development Tools Market Size Report, Industry Share, Analysis, Growth, Forecast,2032

COVID-19 Vaccine Development Tools Market Insights

According to Zion Market Research, the global COVID-19 Vaccine Development Tools Market was worth USD 7.12 Billion in 2023. The market is forecast to reach USD 15.46 Billion by 2032, growing at a compound annual growth rate (CAGR) of 9% during the forecast period 2024-2032. The report offers a comprehensive analysis of the market, highlighting the factors that will determine growth, potential challenges, and opportunities that could emerge in the COVID-19 Vaccine Development Tools Market industry over the next decade.

Request Free Sample

The report offers an assessment and analysis of the COVID-19 Vaccine Development Tools market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2024 to 2032 based on revenue (USD Billion).

COVID-19 Vaccine Development Tools Market: Outlook

The development of vaccines for COVID-19 is key for the global economy to return to normalcy and hence various efforts & investments have been made by many countries for developing vaccines for offering protection to individuals against the SARS-CoV-2 virus.

According to NCBI, till March 2021, nearly 13 vaccines were approved for use and nearly more than 90 vaccines were undergoing phases of clinical trials. In addition to this, artificial intelligence and machine learning have proved to be effective tools in developing COVID-19 vaccines. According to WHO, major components in vaccine development include antigens, residuals, preservatives, diluents, stabilizers, and surfactants and are manufactured by reputed pharma firms Pfizer, BioNTech, and Merck.

Furthermore, vaccine development can take many years of research before it can be approved for medical use by statutory (medical) authorities. Vaccine Inoculation for larger populations becomes possible only after the approval of vaccines. After the development of a new vaccine, it is tested in three phases. Phase I or the preclinical phase includes testing of vaccines on animals and then on a limited number of individuals to record or report stimulation of the immune system due to vaccine injection.

Phase II testing includes vaccine inoculation in many persons involving old persons & children, thereby proving the safety of vaccine inoculation in persons belonging to different age groups. The final phase includes phase III clinical trials of vaccines performed on a large percentage of the population.

Apparently, these phase III clinical studies determine the effectiveness of vaccines against coronavirus without any side effects, thereby helping researchers in determining the efficiency of vaccines. Based on the success of Phase III trials, healthcare authorities decide on providing restricted approval for vaccines. After that, state officials review the overall outcomes of clinical trials and based on that decide on fully approving the production & use of vaccines.

Request Free Sample

COVID-19 Vaccine Development Tools Market: Growth Drivers

An increase in the number of vaccine producers in both emerging economies and developed countries will boost the growth of the COVID-19 vaccine development tools market in the upcoming years. Large-scale use of AI tools in the development of the COVID-19 vaccine and a surge in strategic alliances & partnerships between various pharma firms facilitating intense research on vaccine development & production will enhance the expansion of the COVID-19 vaccine development tools industry in the foreseeable future.

Citing an instance, AstraZeneca entered into a partnership with Serum Institute in India for developing Covishield Vaccine. Another instance is of Sanofi aiding the production of the COVID-19 vaccine by combining Pfizer-BioNtech firms through the offering of services of bottle filling & packing for vaccines later. Favorable government legislation & incentives will prop up the expansion of industry in the years ahead.

Furthermore, the need for avoiding COVID-19 vaccine manufacturing delays will promulgate growth of the Covid-19 vaccine development tool market over the forthcoming years. Enormous funding of research & development activities by private firms as well as government organizations for developing effective vaccines against COVID-19 for combating the spread of the COVID-19 pandemic along with reducing its intensity & effect through enhancing human body immunity will steer market trends.

COVID-19 Vaccine Development Tools Market: Report Scope

COVID-19 Vaccine Development Tools Market: Regional Landscape

Asia Pacific To Contribute Major Market Share During 2021-2028

The expansion of the COVID-19 vaccine development tools market in the Asia Pacific during the assessment period can be credited to a prominent surge in vaccine development for COVID-19 in countries such as India, Israel, and China. Furthermore, determining of new COVID genome in the initial stage through the use of modern sequencing tools by researchers of the sub-continent will expedite the business landscape in the Asia Pacific over the ensuing years. Additionally, large-scale utilization of genome sequencing tools, viral structure examination tools, and immune response profiling systems for developing new vaccines against COVID-19 will steer regional industry trends.

COVID-19 Vaccine Development Tools Market: Competitive Landscape

Key players profiled in the study include

• Thermo Fisher Scientific. Inc.
• Pfizer Inc.
• Celerion, Sartorius AG
• Cole-Parmer Instrument Company
• LLC
• STEMCELL Technologies Inc.
• Illumina. Inc.
• AB Sciex Private Limited
• Agilent Technologies
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Merck KgaA
• Shimadzu Corporation
• PerkinElmer Inc.
• Eurofins Scientific
• Aurora Biomed Inc.

The global COVID-19 Vaccine Development Tools Market is segmented as follows:

By Technology

• Lab Technologies
• PCR & qPCR
• Flow Cytometry
• Spectrometry
• Electron Microscopy
• Next Generation Sequencing

By End-Use

• CROs
• Pharma & BioPharma Firms

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa